Jung Kwan Jang, Korea’s top ginseng product manufacturer, said it conducted a seminar focused on the efficacy and safety of red ginseng during the International Conference on the Science of Botanicals, held in Oxford, Miss., from April 15 to 18.The International Conference on the Science of Botanica
SK biopharmaceuticals said Thursday it has signed a technology transfer agreement with a Chinese joint venture company, Ignis Therapeutics, for a non-narcotic pain treatment candidate worth 80.4 billion won ($58 million).Under the agreement, SK biopharmaceuticals will transfer the global development
Celltrion announced its decision to further buy back and retire its own shares as part of its ongoing efforts to stabilize its stock price and enhance shareholder value.The company stated that it would purchase approximately 436,047 shares for a total acquisition cost of about 75 billion won ($54.1
Samsung Bioepis has achieved a significant milestone by obtaining the first domestic approval for a biosimilar referencing Janssen's Stelara, Epyztek (ingredient: ustekinumab), on Thursday.Stelara, originally developed by Janssen, is utilized in the treatment of plaque psoriasis, psoriatic arthritis
Celltrion said Yuflyma (ingredient: adalimumab), a biosimilar referencing Humira, has been included in the formulary of one of the top three pharmacy benefit managers (PBMs) in the U.S. The three largest PBMs in the U.S., which include CVS Health, Express Scripts, and Optum, collectively manage abou
KBIOHealth (Osong Medical Innovation Foundation) has set up an office in Japan, raising expectations of cooperation between the two countries’ biotech industries.KBIOHealth said it opened an office (KBIOHealth JAPAN Office) in Shonan iPark, located in Kanagawa Prefecture, and held a signboard-hangin
ViGenCell said Monday that it had initiated the Cohort 3 study, the final step of the phase 1 clinical trial of VT-Tri(1)-A for treating acute myeloid leukemia (AML).VT-Tri(1)-A is ViGenCell's first-in-class treatment for AML. It targets multiple common antigens. Last September, it began enrolling p
Pinotbio is increasing its competitiveness on the global stage by emphasizing effectiveness and safety by combining the “PBX-7 Series” and “sequential cleavage linker.”Pinotbio, an ADC platform company, said Monday that it unveiled preclinical results of its ADC platform at the American Association
Celltrion has embarked on a partnership with the Crohn's & Colitis Foundation (CCF), the largest patient advocacy group for inflammatory bowel disease (IBD) in the U.S., aiming to boost awareness and improve perceptions of IBD, a chronic inflammatory condition of the gastrointestinal tract.The CCF,
CG Bio, a Korean generative medicine developer, said Friday that it participated in the Aesthetic & Anti-Aging Medicine World Congress (AMWC) 2024 in Monaco from March 27 to 29, showcasing its aesthetic total solution products.AMWC is the world's largest plastic surgery and aesthetic clinic congress
Samsung Bioepis said it has commenced global phase 3 clinical trials for its biosimilar, SB27, a biosimilar referencing Keytruda, a blockbuster cancer treatment developed by MSD.SB27 marks the company's eleventh biosimilar pipeline, illustrating its ongoing commitment to expanding its portfolio in t
In a troubling trend for the biotechnology sector in Korea, several companies are on the brink of delisting from the tech-heavy Kosdaq due to failing to secure necessary audit approvals amidst a harsh investment climate and lackluster sales and research outcomes.According to reports from the Korea E
Samsung Bioepis said it domestically released Epysqli (ingredient: eculizumab), a biosimilar referencing Soliris, at a much lower price than the original, on Monday. Soliris, developed by Alexion Pharmaceuticals and marketed by AstraZeneca, is used for treating rare conditions such as paroxysmal noc
Gencurix, NGeneBio's largest shareholder, has sold some of its shares to 10 people, including NGeneBio CEO Choi Dae-chul, drawing attention to its background.As a result of the stock transfer, the largest shareholder of NGeneBio has changed to KT, Korea's second-largest wireless carrier, which found
oncoMASTER, a Korean cancer precision medicine company, said it has been designated as a member of Nvidia's startup incubation program Inception.oncoMASTER is a subsidiary of Korea University Medical Technology Holdings and was established based on the achievements of the K-Master Project Corps, whi
Orion, a Korean confectionary company, has become the largest shareholder of antibody-drug conjugate (ADC) drug developer LigaChem Biosciences (formerly LegoChem Biosciences) by paying all of its stock purchase prices.On March 29, Orion announced that it has completed the payment of 548.5 billion wo
Quratis, a Kosdaq-listed biotech company, said Friday that it has decided to establish a local corporation in the Philippines to tap into the country's tuberculosis vaccine market.Quratis has submitted an investigative new drug (IND) application for a phase 2b/3 clinical trial of “QTP101,” a TB vacc
CHA Biotech and Centenaire Biosciences have agreed to expand their collaboration on natural killer (NK) cell-antibody combination research. To this end, CHA Biotech transferred its NK cell therapeutic candidate to Centenaire Biosciences.The two companies will combine CHA Biotech's NK cells with Cent
Rophibio, a Korean biologics manufacturer, said Wednesday that it has entered into an agreement with Avantor, a U.S. biotech company, to supply raw materials and provide development support for a biosimilar referencing Keytruda.Keytruda (pembrolizumab) is MSD's blockbuster cancer medicine.The proces
FutureChem said Wednesday that its radiopharmaceutical candidate FC705 for treating prostate cancer has been granted Global Innovative Products on Fast Track (GIFT) designation by the Ministry of Food and Drug Safety.GIFT is a support system to bring highly innovative drugs, such as treatments for l